-
-
Call more information
660-596-2224 -
Author: Vishal Uppal, MBBS, MSc, FRCA ASA Monitor May 2024, Vol. 88, 1–9. When compared with general anesthesia (GA), patients undergoing surgery solely under peripheral nerve blocks (PNBs) are more likely to have improved short-term postoperative pain control, less nausea and vomiting, early discharge from the postanesthesia care unit and hospital, and overall improved patient satisfaction […]
Read MoreAuthor: David P. Martin, MD, PhD, FASA ASA Monitor May 2024, Vol. 88, 7–8. The largest group of committees and editorial boards within ASA resides in the Division of Scientific Affairs, comprising the sections on Publications, Clinical Care, Subspecialties, Education and Research, and the Annual Meeting. Last year in this column, space allowed us to review […]
Read MoreASA Monitor May 2024, Vol. 88, 27. The U.S. Food and Drug Administration (FDA) has granted approval to Thirona’s LungQ™ AI-based clinical software, making it one of few FDA-cleared solutions able to automatically segment pulmonary structures, aiding in lung diagnosis and documentation. LungQ’s analysis improves the understanding of lung anatomy, facilitating minimally invasive treatments for diseases […]
Read MoreAuthors: George Tewfik, MD, MBA, FASA et al ASA Monitor May 2024, Vol. 88, 1–6. Postoperative cognitive dysfunction (POCD) – also referred to as perioperative neurocognitive disorders – and delirium are pathologic states that may develop after surgery and often result in distress to the patient, family members, medical practitioners, and the health care system. Patients […]
Read MoreASA Monitor May 2024, Vol. 88, 27. A 16-week clinical trial conducted by the National Institutes of Health (NIH) showcased promising results for the monoclonal antibody, omalizumab, in reducing allergic reactions to multiple foods among children ages 1 year and older with food allergies. The trial revealed that nearly 67% of participants who underwent omalizumab treatment […]
Read More